Abstract
Background: Adherence to drug treatment and health-related quality of life (HRQL) are two distinct concepts. Generally one would expect a positive relationship between the two. Objectives: The purpose of this study was to assess the relationship between adherence and HRQL. Methods: HRQL was measured using the physical and mental summary measures of the RAND-12 (PHC-12, MHC-12), the SF-12 (PCS-12, MCS-12), HUI-2 and HUI-3. Adherence was assessed using Morisky's instrument. Three longitudinal datasets were used. One dataset included 100 hypertensive patients. Another dataset covered 199 high risk community-dwelling individuals. The third dataset consisted of 365 elderly patients. Spearman's correlation coefficients were used to assess association. Subgroup analyses by type of medication and inter-temporal analyses were also performed. Results: Correlation between adherence and PHC-12 ranged from 0.08 (p = 0.26) to 0.22 (p < 0.01). Correlations between adherence and MHC-12 ranged from 0.11 (p = 0.11) to 0.15 (p < 0.01). Similar results were observed using HUI-2, HUI-3, and SF-12 as well as by type of medication and in the lagged analyses. Conclusions: Correlations between HRQL and adherence were positive but typically weak or negligible in magnitude.
Similar content being viewed by others
References
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67–74.
Hume AL. Applying quality of life data in practice: Considerations for antihypertensive therapy. J Fam Pract 1989; 28(4): 403–407.
Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334(13): 835–840.
Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9(8): 887–900.
Green LW, Kreuter MW. Health Promotion Planning: An Educational and Environmental Approach. 2nd ed., Mountain View CA: Mayfield Publishing Company, 1991.
Health Behavior and Health Education. 2nd ed., San Francisco: Josey-Bass Publishers, 1997.
Adherence to Treatment in Medical Conditions. Amsterdam: Harwood Academic Publishers, 1998.
The Handbook of Health Behavior Change. 2nd ed., New York: Springer Publishing Co., 1998.
Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991; 48(9): 1978–1988.
Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984; 100(2): 258–268.
Schaub AF, Steiner A, Vetter W. Compliance to treatment. Clin Exp Hypertens 1993; 15(6): 1121–1130.
Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975; 13(1): 10–24.
Kirscht JP, Rosenstock IM. Patient adherence to antihypertensive medical regimens. J Community Health 1977; 3(2): 115–124.
Fincham J. The drug use process. In: Fincham J, Wertheimer A (ed), Pharmacy and the U.S. Health Care System. New York: Pharmaceutical Products Press, 1998; 394–438.
Haynes R. Determinants of Compliance: The Disease and the Mechanics of Treatment. Compliance in Health Care. Baltimore: The Hopkins University Press, 1979; 49–62.
Keeler EB, Brook RH, Goldberg GA, Kamberg CJ, Newhouse JP. How free care reduced hypertension in the health insurance experiment. JAMA 1985; 254(14): 1926–1931.
Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med 1987; 317(9): 550–556.
Evans RG, Stoddart GL. Producing health, consuming health care. Soc Sci Med 1990; 31(12): 1347–1363.
Grootendorst P, Feeny D, Furlong W. Health Utilities Index Mark 3: Evidence of construct validity for stroke and arthritis in a population health survey. Med Care 2000; 38(3): 290–299.
Billups SJ, Malone DC, Carter BL. The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy 2000; 20(8): 941–949.
Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 1999; 13(3): 185–197.
Pippalla RS, Chinburapa V, Duval R, Akula RS. Interrelationship of quality of life, compliance, clinical outcomes and life satisfaction: A cross-sectional study on hypertensive geriatrics. J Clin PharmTherap 1997; 22: 357–369.
Sung JCY, Nichol MB, Venturini V, Bailey KL, McCombs JS, Cody M. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Man Care 1998; 4: 4121–1430.
Kassam R, Farris KB, Burback L, Volume CI, Cox CE, Cave A. Pharmaceutical care research and education project: Pharmacists' interventions. J Am Pharm Assoc (Wash) 2001; 41(3): 401–410.
Volume CI, Farris KB, Kassam R, Cox CE, Cave A. Pharmaceutical care research and education project: Patient outcomes. J Am Pharm Assoc (Wash) 2001; 41(3): 411–420.
Ware J, Snow K, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
Hays RD. RAND-36 Health Status Inventory. San Antonio: The Psychological Corporation (Harcourt Brace & Company), 1998.
Health Utilities Inc. Health-Related-Quality-of-Life. http:// www.healthutilities.com/HUI-frames.htm, Accessed July 12, 2002.
Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. Cmaj 2000; 163(3): 265–271.
Feeny DH, Torrance GW, Furlong WJ. Health utilities index. In: Spilker B (ed), Quality of Life and Pharmaco-economics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996: 239–252.
Furlong W, Feeny D, Torrance GW, et al. Multiplicative multi-attribute utility function for the health utilities index mark 3 (HUI3) system: A technical report. 98-11. 1998. McMaster University, Centre for Health Economics and Policy Analysis, 1998.
Little R, Rubin D. Statistical Analysis with Missing Data. New York: John Wiley and Sons, 1987.
Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42(10): 773–778.
Lawrence WF, Fryback DG, Martin PA, Klein R, Klein BE. Health status and hypertension: A population-based study. J Clin Epidemiol 1996; 49(11): 1239–1245.
Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991; 48: 1978–1988.
Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension 1980; 2(6): 757–764.
Stewart M. The validity of an interview to assess a patient's drug taking. Am J Prev Med 1987; 3(2): 95–100.
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261(22): 3273–3277.
Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11(6): 1189–1197.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Côté, I., Farris, K. & Feeny, D. Is adherence to drug treatment correlated with health-related quality of life?. Qual Life Res 12, 621–633 (2003). https://doi.org/10.1023/A:1025180524614
Issue Date:
DOI: https://doi.org/10.1023/A:1025180524614